The Inaugural ALK+ Day Is November 15, During Lung Cancer Awareness Month. (Photo: Business Wire)

In recognition of this month's Lung Cancer Awareness Month, ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the launch of an inaugural awareness day for anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) patients and their care partners. The awareness day is the first of its kind to specifically focus on ALK+ NSCLC and will be held on November 15 th and subsequently on the third Tuesday of each November.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161114005418/en/
The inaugural ALK+ Day is November 15, during Lung Cancer Awareness Month. (Photo: Business Wire)

The inaugural ALK+ Day is November 15, during Lung Cancer Awareness Month. (Photo: Business Wire)

"This year we're recognizing our 25 year anniversary as a company and we are extremely proud of our research efforts for rare cancers. This inaugural ALK+ Day, a collaborative engagement with the lung cancer patient advocacy community, has the goal to place progress made in the ALK+ NSCLC space within the context of advances made in non-small cell lung cancer research," stated Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer at ARIAD. "As we engage with the lung cancer community we aim to help raise awareness about ALK+ NSCLC and encourage others to join the conversation about the R&D progress in this rare cancer space, as well as the importance of mutation testing."

This month, ARIAD seeks to support patient education and community, while also advancing innovative science focused on rare cancers. Through its collaboration with the Lung Cancer Foundation of America (LCFA), the community is encouraged to talk about "The Little Things" that lung cancer patients are thankful for, that their lungs allow them to do, using the social media hashtag #LittleThingsLCFA during the month of November.

"We are excited to work with ARIAD on building awareness about ALK+ non-small cell lung cancer during Lung Cancer Awareness Month in order to highlight the progress and work still-to-be-done in battling lung cancer. Our mission is the dramatic improvement in survivorship of lung cancer patients through the funding of transformative science, with the ultimate goal of curing the disease," said Kim Norris, president and co-founder of the Lung Cancer Foundation of America.

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)